Oral valproic acid vs placebo
Acquiring the ability to stand or walk · ambulatory adults with SMA type III
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
4,695 questions · 4,979 findings · 433 reviews
No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%
Oral valproic acid vs placebo
Change in quality of life · ambulatory adults with SMA type III
1 finding from 1 review
- no estimate extracted28 participantsModerate
Oral valproic acid vs placebo
Change in pulmonary function · ambulatory adults with SMA type III
1 finding from 1 review
- no estimate extracted24 participantsLow
Oral valproic acid vs placebo
Time from beginning of treatment until death or full‐time ventilation · ambulatory adults with SMA type III
1 finding from 1 review
- no estimate extracted33 participantsLow
Oral valproic acid vs placebo
Adverse events related to treatment · ambulatory adults with SMA type III
Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
- RR 0.8 [0.44, 1.44]33 participantsLow
Oral hydromorphone vs placebo
Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral hydromorphone vs placebo
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral hydromorphone vs placebo
Lack of efficacy withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain
1 finding from 1 review
- no estimate extracted1 study · 94 participantsVery low
Oral hydromorphone vs placebo
Adverse event withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain
1 finding from 1 review
- no estimate extracted1 study · 94 participantsVery low
Oral hydromorphone vs placebo
Serious adverse events · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral hydromorphone vs placebo
Deaths · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Dexamethasone: oral vs intramuscular – fetal/neonatal outcomes
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes any known death after randomisation (fetal, neonatal, child, child… compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
- Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes onlyRR 1.48 [0.45, 4.9]1 study · 183 participantsVery low
Dexamethasone: oral vs intramuscular – fetal/neonatal outcomes
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes respiratory distress syndrome compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
- Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes onlyRR 1.15 [0.75, 1.77]1 study · 183 participantsVery low
Dexamethasone: oral vs intramuscular – fetal/neonatal outcomes
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
- Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes onlyRR 4.24 [0.96, 18.83]1 study · 183 participantsVery low
Dexamethasone: oral vs intramuscular – fetal/neonatal outcomes
Necrotising enterocolitis · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes necrotising enterocolitis compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
- Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes onlyRR 5.09 [0.63, 41.45]1 study · 183 participantsVery low
Dexamethasone: oral vs intramuscular – fetal/neonatal outcomes
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
- Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Oral drug treatment vs topical treatments
Primary outcome 1: Number of clinical recurrences per participant per year · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Oral drug treatment vs topical treatments
Primary outcome 2: Clinical recurrence at 6 months · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 6 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
- RR 1.66 [0.83, 3.31]3 studies · 206 participantsVery low
Oral drug treatment vs topical treatments
Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 12 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
- RR 0.95 [0.71, 1.27]3 studies · 206 participantsVery low
Oral drug treatment vs topical treatments
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
- no estimate extracted3 studies · 3 participantsVery low